P16-45. High avidity CD4+ T cell response directed to an immunodominant Gag epitope in HIV controllers: an ANRS EP36 study by Vingert, B et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Poster presentation
P16-45. High avidity CD4+ T cell response directed to an 
immunodominant Gag epitope in HIV controllers: an ANRS EP36 
study
B Vingert6, S Perez-Patrigeon6, P Jeannin6, O Lambotte1, F Boufassa2, 
F Lemaître3, WK Kwok4, I Theodorou5, J Delfraissy1, J Thèze6 and 
LA Chakrabarti*6
Address: 1AP-HP, Department of Internal Medicine and Infectious Diseases, Bicêtre Hospital, Le Kremlin-Bicêtre, France, 2INSERM U822, Bicêtre 
Hospital, Le Kremlin-Bicêtre, France, 3G5 Dynamiques des Réponses Immunes, Institut Pasteur, Paris, France, 4Benaroya Research Institute at 
Virginia Mason, Seattle, USA, 5INSERM U543, Pitié-Salpêtrière Hospital, Paris, France and 6Unité d'Immunogénétique Cellulaire, Institut Pasteur, 
Paris Cedex 15, France
* Corresponding author    
Background
Emerging evidence indicates that HIV controllers contain
HIV-1 replication through very active cellular immune
responses, though how such responses can persist over
time without exhaustion or waning is not yet understood.
To investigate the nature of memory CD4+ T cells respon-
sible for sustained anti-HIV responses, we characterized
their capacity to generate primary cell lines specific for
immunodominant Gag peptides.
Methods
CD4+ T cell lines were derived from patients who sponta-
neously controlled HIV replication (HIV controller group,
n = 17) and patients who achieved viral control following
successful antiretroviral therapy (HAART group, n = 20).
Cell lines were compared for growth kinetics, Vβ reper-
toire, and sensitivity to antigen.
Results
Specific cell lines were obtained at high rate for both HIV
controllers (16/17) and efficiently treated patients (19/
20) in response to the immunodominant Gag293 pep-
tide. However, lines from controllers showed faster
growth kinetics than those of treated patients. After nor-
malizing for growth rates, IFN-γ responses directed against
the immunodominant Gag293 peptide showed higher
functional avidity in HIV controllers, while responses to
Gag161, Gag263, or CMV peptides did not differ between
groups. Characterization of Gag293-specific CD4+ T cells
through MHC class II tetramer labeling revealed a diverse
Vβ repertoire, suggesting that multiple clones contributed
to the high avidity CD4+ T cell population in HIV control-
lers. The high functional avidity of the Gag293-specific
response could be explained, at least in part, by a high
avidity interaction between the TCR and the peptide-
MHC complex, as demonstrated by class II tetramer bind-
ing.
Conclusion
This study provides evidence that HIV controllers harbor
a pool of high avidity memory CD4+ T cell precursors
directed against an immunodominant Gag peptide. The
capacity to mount a rapid CD4 response in the presence
of minimal amounts of Gag antigen helps explain how
HIV controllers maintain an active antiviral response in
the face of very low viremia.
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